Antares Vision Group to Debut Prefilled Syringe Inspection and Leak Detection System at Interphex NYC 2026

Why It Matters

The launch gives pharmaceutical manufacturers a faster, more integrated quality‑control line for high‑value biologics, reducing waste and compliance risk while supporting the surge in GLP‑1 and other injectable therapies.

Key Takeaways

• CY Series inspects up to 200 syringes per minute
• Handles glass or plastic syringes up to 15 mm diameter
• ETFS‑300 combines labeling and plunger‑rod insertion in one
• Easy TB offers tool‑free format changes under one minute
• INSPECTA unifies all inspection hardware under single interface

Pulse Analysis

The growing reliance on prefilled syringes for biologics, vaccines, and specialty injectables has intensified demand for high‑throughput, reliable inspection technologies. Antares Vision’s CY Series addresses this need by marrying high‑speed visual inspection with patented high‑voltage leak detection, delivering up to 200 units per minute while accommodating diverse viscosities and container materials. By automating integrity checks that traditionally required multiple stations, manufacturers can shorten line times, lower reject rates, and meet stringent regulatory expectations for sterility and dosage accuracy.

Space constraints on modern production floors make multi‑function equipment especially valuable. The ETFS‑300 merges thermal‑transfer labeling, print verification, and precise plunger‑rod insertion into a single footprint, eliminating the need for separate labeling and assembly lines. Meanwhile, the Easy TB manual inspection unit provides a flexible, tool‑free solution for small‑batch or R&D runs, enabling rapid format changes and detailed defect trending without disrupting larger automated lines. This modular approach lets facilities scale inspection capacity without costly capital expansions.

Beyond inspection, Antares introduces INSPECTA, a unified software layer that integrates vision sensors, line‑scan cameras, and smart devices across the production line, simplifying operator training and data management. Coupled with its cold‑chain management suite, which tracks temperature‑sensitive GLP‑1 products via barcode and forthcoming RFID integration, the portfolio offers end‑to‑end traceability from fill to distribution. Together, these innovations position Antares as a key enabler for the next wave of injectable therapeutics, where speed, accuracy, and temperature control are paramount.